Clinical trial
A Multi-Center, Adaptive Phase 2, Randomized, Double-Blind, Placebo- and Active-Controlled (Sitagliptin), Parallel Group Study to Evaluate the Safety and Efficacy of TTP399 Following 6 Months Administration in Subjects With Type 2 Diabetes Mellitus on A Stable Dose of Metformin
NCT02405260 is registered in ClinicalTrials.gov with vTv Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-Center, Adaptive Phase 2, Randomized, Double-Blind, Placebo- and Active-Controlled (Sitagliptin), Parallel Group Study to Evaluate the Safety and Efficacy of TTP399 Following 6 Months Administration in Subjects With Type 2 Diabetes Mellitus on A Stable Dose of Metformin
- Lead sponsor
- vTv Therapeutics
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- March 31, 2015
- Completion date
- September 30, 2016
- Enrollment
- 190 (actual)
- Sites
- 20
Conditions
As the registry lists them; a condition with its own page is linked.